Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

datum dental teeth biomaterial

News and Trends 19 Jun 2018

Biomaterial to Regenerate Teeth Approved in Europe

The Israeli company Datum Dental has received approval to launch a biomaterial for dental implants in Europe and Canada. Datum Dental has developed a biomaterial specifically designed to help the body regenerate real bone tissue after dental operations. Launched in the US last year, the biomaterial has now received CE marking in Europe and approval […]

June 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Bioprinting

In Depth 19 Jun 2018

Bioprinting in Europe: Fact or Fiction?

A lot of fantasy surrounds bioprinting: everyone has in mind advanced reactors that would print, in just a few seconds or minutes, a missing body part or even a fully functioning organ. Still, as the technology gains in maturity, it’s no longer utopian to imagine tissue implants created from scratch. The bioprinting market is expected […]

June 19, 2018 - 3 minutesmins - By External Contributor

Idorsia Arterial Constriction

More News! 18 Jun 2018

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […]

June 18, 2018 - 2 minutesmins - By Alexander Burik

ViiV Healthcare COver

News and Trends 15 Jun 2018

London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials

ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […]

June 15, 2018 - 2 minutesmins - By Alexander Burik

Aleph Farms Cover

Startup Scout 15 Jun 2018

This Israeli Biotech is Making Cultured Meat More Like the Real Thing

Today, we’re in Ashdod, Israel, visiting Aleph Farms, a biotech that’s making cultured meat grown in a 3D environment that resembles the texture of natural meat. Mission: Founded in 2017, Aleph Farms uses cell samples taken from living cattle to create cultured meat. The cells are then grown in a 3D environment, which can help […]

June 15, 2018 - 2 minutesmins - By Alexander Burik

Blackgrass Herbicide Cover

News and Trends 14 Jun 2018

Device Helps Protect Cereals by Diagnosing Herbicide Resistance in Weeds

Mologic and Newcastle University have launched a diagnostic device that provides rapid information on herbicide resistance for a common weed, which could help cut major losses for the British agricultural industry. The partnership between academia and industry has developed a device that can diagnose herbicide resistance in the blackgrass weed, which could help farmers protect […]

June 14, 2018 - 2 minutesmins - By Alexander Burik

ADVERTISEMENT

Neurodegenerative Cover

News and Trends 14 Jun 2018

Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease

Spanish researchers have developed a way to diagnose neurodegenerative diseases by analyzing eye movements. The Madrid-based research team and its spin-off company Aura Innovative Robotics have developed a diagnostic test for neurodegenerative disease that tracks a patient’s eye movements and analyzes the data using machine learning. The diagnostic test, called OSCANN Desk, is currently being […]

June 14, 2018 - 2 minutesmins - By Alexander Burik

Cellectis Cover Image

News and Trends 13 Jun 2018

French Biotech Develops a New Generation of Safer CAR-T Cells

Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of CAR-T cell therapies generated from both patient and donor cells. Cellectis, a French biotech focused on developing CAR-T therapies from donor cells, has published a study in the journal Scientific Reports describing technological advances that could improve the […]

June 13, 2018 - 2 minutesmins - By Alexander Burik

pluristem cell therapy peripheral artery disease

News and Trends 13 Jun 2018

Placenta Cell Therapy Improves Mobility in Patients with Peripheral Artery Disease

The Israeli biotech Pluristem has Phase II data indicating that its cell therapy made of placenta cells can help patients suffering from peripheral artery disease recover their mobility. The trial, run in the US, Germany, South Korea and Israel, enrolled 172 patients with intermittent claudication, an early stage of peripheral artery disease where the legs […]

June 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

CAR T Celyad Small Cover

Interview 13 Jun 2018

CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead

CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were exhausted. However, the technology still has a long road ahead before becoming a widespread treatment option. Philip spoke to Christian Homsy, CEO of Celyad, at our Refresh Meetup in Brussels about the challenges CAR-T cell […]

June 13, 2018 - 5 minutesmins - By Alexander Burik

Vaccinesspidersilk

News and Trends 12 Jun 2018

Spider Silk Shows Promise in Vaccine Field

Swiss and German scientists have engineered spider-silk microparticles that can be used to protect a vaccine particle, allow it to enter immune cells and trigger T-cell immunity without toxic effects. The team, partnered by AMSilk — the German biotech behind Adidas’ biodegradable shoes, hopes their technique will allow more targeted and stable vaccines against difficult targets […]

June 12, 2018 - 3 minutesmins - By Helen Albert

crispr therapy cancer risk

News and Trends 11 Jun 2018

Scientists Warn CRISPR Therapy Could Cause Cancer as First Human Trials Take Place

A study at Karolinska Institutet in Sweden has revealed that CRISPR-Cas9 gene editing could favor mutations in the most common cancer-causing gene. What does it mean for the first CRISPR therapy trials in humans? CRISPR-Cas9 has taken the life sciences field by storm, making gene editing simpler and faster than ever. Although CRISPR-Cas9 gene […]

June 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT